Gambia will make it mandatory for all pharmaceutical products from India to be inspected and tested prior to shipment from July 1, according to Gambian government documents reviewed by Reuters, the first known restrictions on national exports following the deaths of dozens of children linked to Indian-made cough syrups.
Featured Posts
A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday will vote on whether to recommend the use of recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections in older adults.
The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim’s drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Wegovy maker Novo Nordisk on Tuesday said it had sued some medical spas and wellness clinics in the United States for selling products claiming to contain semaglutide, the key ingredient in its popular weight-loss and diabetes drugs.
An Indian maker of a paracetamol syrup that Nigerian authorities have found toxic told Reuters on Tuesday that tests by a private Indian laboratory found them of “standard quality”, as Indian authorities launch their own investigation.
Merck & Co. said on Tuesday its blockbuster immunotherapy Keytruda failed to meet one of the two main goals in a late-stage study testing it as a treatment option for a type of advanced gastric cancer.
Eli Lilly and Co. agreed to buy Dice Therapeutics Inc. for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer.
BioNTech, a German company specializing in mRNA-based vaccines, is facing its first lawsuit in Germany related to alleged side effects of its COVID-19 vaccine, developed in partnership with Pfizer and authorized for emergency use in 158 countries, Reuters reported last week. But in the U.S., vaccine makers are protected from any such liability until October 2024, thanks to a provision the federal government put forth at the start of the pandemic.
Novo Nordisk’s launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.
Eli Lilly’s head-to-head CHALLENGE-MIG trial missed its primary endpoint Friday, failing to establish the statistical superiority of the company’s Emgality (galcanezumab-gnlm) over Pfizer’s Nurtec orally disintegrating tablets (rimegepant).